Beijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation

Bulletin Express

02/06

Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the filing process for its H Share Full Circulation plan. According to the notice, the filing remains valid for 12 months from the issuance date.

The company intends to apply to The Stock Exchange of Hong Kong Limited for the conversion and listing of the relevant shares. The implementation plan for the H Share Full Circulation has not been finalized, and further updates will be provided in accordance with applicable regulations and requirements.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1194401477"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194401477\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194401477?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194401477","market":"us","top_or_hot":-1,"title":"Beijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation","media":"Bulletin Express","content":"<p>Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the filing process for its H Share Full Circulation plan. According to the notice, the filing remains valid for 12 months from the issuance date.</p>\n<p>The company intends to apply to The Stock Exchange of Hong Kong Limited for the conversion and listing of the relevant shares. The implementation plan for the H Share Full Circulation has not been finalized, and further updates will be provided in accordance with applicable regulations and requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-06 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the filing process for its H Share Full Circulation plan. According to the notice, the filing remains valid for 12 months from the issuance date.</p>\n<p>The company intends to apply to The Stock Exchange of Hong Kong Limited for the conversion and listing of the relevant shares. The implementation plan for the H Share Full Circulation has not been finalized, and further updates will be provided in accordance with applicable regulations and requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"华昊中天医药-B","start_time":0,"source_url":"","article_id":"1194401477","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194401477","pubTimestamp":1770391303,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02563":"华昊中天医药-B"},"translate_title":"北京映泰药业(2563)收到证监会H股全流通备案通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":1},"content_text":"Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the filing process for its H Share Full Circulation plan. According to the notice, the filing remains valid for 12 months from the issuance date.\nThe company intends to apply to The Stock Exchange of Hong Kong Limited for the conversion and listing of the relevant shares. The implementation plan for the H Share Full Circulation has not been finalized, and further updates will be provided in accordance with applicable regulations and requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}